Company intelligence / Profile preview
Mitsubishi Tanabe Pharma
- Ownership
- Private
- Employees
- ~5000
- Development stage
- Other
Overview
Mitsubishi Tanabe has commercialized innovative drugs (e.g. edaravone for ALS, teneligliptin for diabetes). Its pipeline includes late-stage assets in CNS, immunology, oncology (including Phase 3 schizophrenia therapy and oncology ADCs); the company has more than 140 marketed drugs and participates in global regulatory and commercial activity, most recently advancing an ADC for lymphoma and an oncology asset for solid tumors.[6][10][5][2]
- Therapeutic areas
- ImmunologyEndocrinologyRheumatologyPsychiatryGastroenterologyOncologyNeurology
- Modalities
- Small moleculeMonoclonal antibodyAntibody-drug conjugateVaccineProtein
- Industry
- Biotech
Drug pipeline
6 assets5 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Mitsubishi Tanabe Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Mitsubishi Tanabe Pharma.